Opdivo (nivolumab)

pCPA File Number: 21745
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT)
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CADTH Project Number:
PC0253
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable